Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.
Respiratory syncytial virus (RSV) remains a significant cause of morbidity and mortality in infants and young children, immunocompromised patients and the elderly. Despite the high disease burden, an effective and safe vaccine is lacking, although several candidates are currently in development. Current treatment for RSV infection remains largely supportive and RSV-specific options for prophylaxis are limited to palivizumab. In the past few years, novel therapeutic options including nanobodies, polyclonal and monoclonal antibodies have emerged and there are several products in preclinical and Phase-I, -II or -III clinical trials. The major target for antiviral drug development is the surface fusion (F) glycoprotein, which is crucial for the infectivity and pathogenesis of the virus. Solving the structures of the two conformations of the RSV F protein, the prefusion and postfusion forms, has revolutionized RSV research. It is now known that prefusion F is highly superior in inducing neutralizing antibodies. In this section we will review the stages of development and availability of different antibodies directed against RSV for the prevention and also for treatment of acute RSV infections. Some of these newer anti-RSV agents have shown enhanced potency, are being explored through alternative routes of administration, have improved pharmacokinetic profiles with an extended half-life, and may reduce design and manufacturing costs. Management strategies will require targeting not only high-risk populations (including adults or immunocompromised patients), but also previously healthy children who, in fact, represent the majority of children hospitalized with RSV infection. Following treated patients longitudinally is essential for determining the impact of these strategies on the acute disease as well as their possible long-term benefits on lung morbidity.
Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. Electronic address: asuncion.mejias@nationwidechildrens.org.
Asuncion
A
Mejias
Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Cristina
C
Garcia-Maurino
Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA; Department of Pediatrics, Hospital Infantil Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Rosa
R
Rodriguez-Fernandez
Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Mark E
ME
Peeples
Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. Electronic address: octavio.ramilo@nationwidechildrens.org.
Octavio
O
Ramilo
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000494:pharmacology; D000914:Antibodies, Viral / Q000008:administration & dosage* / Q000302:isolation & purification* / Q000494:pharmacology; D000998:Antiviral Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000494:pharmacology; D002986:Clinical Trials as Topic; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control* / Q000628:therapy*; D012136:Respiratory Syncytial Viruses / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000998:Antiviral Agents
Monoclonal antibodies; Nanobodies; RSV
Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):223-33
19689261
Microbes Infect. 2003 Feb;5(2):123-33
12650770
Lancet. 1999 Aug 14;354(9178):541-5
10470697
J Infect Dis. 2009 Aug 1;200(3):439-47
19545210
Virology. 2002 Mar 15;294(2):296-304
12009871
J Gen Virol. 2015 Sep;96(9):2543-56
26297201
Clin Microbiol Rev. 1999 Jul;12(3):383-93
10398671
Nature. 2013 Sep 19;501(7467):439-43
23955151
Antimicrob Agents Chemother. 2013 Dec;57(12):6147-53
24080653
Science. 2013 May 31;340(6136):1113-7
23618766
PLoS Med. 2013 Nov;10(11):e1001549
24265599
Biochem Biophys Res Commun. 2001 Jan 12;280(1):188-95
11162498
Nat Struct Mol Biol. 2010 Feb;17(2):248-50
20098425
J Infect. 2015 Jun;71 Suppl 1:S80-7
25922289
J Infect Dis. 2011 Dec 1;204(11):1692-701
21998474
Lancet Respir Med. 2015 Nov;3(11):888-900
26411809
J Virol. 2001 Aug;75(15):6825-34
11435561
Thorax. 2010 Dec;65(12):1045-52
20581410
Antimicrob Agents Chemother. 2005 Nov;49(11):4700-7
16251314
Antimicrob Agents Chemother. 1999 May;43(5):1183-8
10223933
Pediatrics. 2010 Jan;125(1):e35-51
20008423
Pediatr Infect Dis J. 1999 Feb;18(2):115-22
10048682
Pediatrics. 1997 Jan;99(1):93-9
8989345
J Virol. 2002 Jun;76(11):5654-66
11991994
Nat Immunol. 2001 Aug;2(8):732-8
11477410
J Mol Biol. 2007 May 4;368(3):652-65
17362988
Virology. 2000 Jun 5;271(2):264-75
10860881
J Infect Dis. 1997 Nov;176(5):1215-24
9359721
Pediatrics. 2010 Dec;126(6):e1453-60
21098154
J Virol. 2010 Sep;84(18):9632-6
20592094
PLoS One. 2015 Jun 24;10(6):e0130517
26107373
Pediatr Res. 2011 Aug;70(2):186-91
21522037
Lancet. 2012 Dec 15;380(9859):2095-128
23245604
Pediatrics. 1998 Sep;102(3):531-7
9724660
J Infect Dis. 1999 Jul;180(1):35-40
10353858
J Virol. 2001 Nov;75(22):10730-7
11602714
Nat Med. 2011 Aug 14;17(9):1132-5
21841784
Virology. 2014 Jul;460-461:119-27
25010277
Lancet Infect Dis. 2015 Dec;15(12):1398-408
26511956
J Virol. 2011 Aug;85(15):7788-96
21613394
JAMA. 1999 Oct 20;282(15):1440-6
10535434
Curr Top Microbiol Immunol. 2013;372:83-104
24362685
J Infect Dis. 2004 May 15;189(10):1856-65
15122522
J Virol. 1995 Apr;69(4):2667-73
7884920
Pediatr Infect Dis J. 2014 Jul;33(7):703-9
24356256
Viral Immunol. 2000;13(1):125-35
10733174
J Pediatr. 2007 Jul;151(1):34-42, 42.e1
17586188
N Engl J Med. 1993 Nov 18;329(21):1524-30
8413475
Antimicrob Agents Chemother. 2015 Oct 05;60(1):6-13
26438495
PLoS Pathog. 2015 Dec 11;11(12):e1005318
26658574
J Pediatr. 2003 Oct;143(4):532-40
14571236
Pediatr Infect Dis J. 2007 Aug;26(8):733-9
17848887
N Engl J Med. 2009 Feb 5;360(6):588-98
19196675
Pediatrics. 2014 Aug;134(2):415-20
25070315
Antimicrob Agents Chemother. 2004 May;48(5):1811-22
15105140
J Allergy Clin Immunol. 2010 Aug;126(2):256-62
20624638
Infect Disord Drug Targets. 2012 Apr;12(2):98-102
22335500
Pediatrics. 2009 Dec;124(6):1694-701
19736258
Lancet. 2010 May 1;375(9725):1545-55
20399493
J Infect Dis. 2010 May 1;201(9):1404-13
20350162
PLoS Pathog. 2015 Jul 10;11(7):e1005035
26161532
N Engl J Med. 2013 May 9;368(19):1791-9
23656644